Vedolizumab has no effect on the course of non-alcoholic fatty liver disease: A retrospective cohort analysis
- Resource Type
- Authors
- Prabhat Kumar; Ashraf Almomani; Somtochukwu Onwuzo; Antoine Boustany; Eduard Krishtopaytis; Dana Alshaikh; Almaza Albakri; Motasem Alkhayyat; Tareq Kiwan; Imad Asaad
- Source
- Journal of Clinical and Experimental Gastroenterology. 2:14-18
- Subject
- Pharmacology
Ecology
Physics and Astronomy (miscellaneous)
Physiology
General Chemical Engineering
Organic Chemistry
Biomedical Engineering
Pharmaceutical Science
General Physics and Astronomy
Plant Science
General Chemistry
Condensed Matter Physics
Biochemistry
Analytical Chemistry
Surfaces, Coatings and Films
Complementary and alternative medicine
Nuclear Energy and Engineering
Drug Discovery
Molecular Medicine
Agronomy and Crop Science
Ecology, Evolution, Behavior and Systematics
- Language
Background and Aim: Non-Alcoholic Fatty Liver Disease (NAFLD) is the commonest cause of chronic liver disease and is a leading cause of liver transplantation in the United States, with no approved medication to halt or reverse its progression. Recent animal-model prospective trial-suggested that drug Vedolizumab leads to improvement and reversal in the NAFLD-related metabolic derangements. Vedolizumab is an α4β7 integrin-inhibitor that is approved for use in IBD patients. Our study aims to understand Vedolizumab's impact on the course of NAFLD in inflammatory bowel disease (IBD) patients. Methods: We conducted a retrospective cohort analysis of 158 subjects with NAFLD who received Vedolizumab at Cleveland Clinic Foundation (CCF). One cohort of 79 patients with NAFLD who received Vedolizumab were matched with control group of 79 patients. We determined the primary outcome as the response to Vedolizumab measured as Fibrosis-4 (Fib-4) regression to